• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain

tetano

Editor, Senior Moderator
Enferm Infecc Microbiol Clin. 2017 Nov 24. pii: S0213-005X(17)30321-X. doi: 10.1016/j.eimc.2017.10.021. [Epub ahead of print]
[h=1]Prevalence of antibodies and humoral response after seasonal trivalent vaccination against influenza B lineages in an elderly population of Spain.[/h] [Article in English, Spanish]
Mu?oz IS[SUP]1[/SUP], Rello SR[SUP]2[/SUP], Lejarazu RO[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] The aim of this study was to analyze the presence of antibodies against both Yamagata and Victoria influenza B lineages and to check the response after seasonal trivalent vaccination.
[h=4]MATERIALS AND METHODS:[/h] Haemagglutination inhibition assays were performed with pre-and post-vaccination serum samples from 174 individuals ≥65 years of age vaccinated with seasonal trivalent influenza vaccines during the 2006-2007, 2008-2009, 2009-2010 and 2010-2011 vaccine campaigns.
[h=4]RESULTS:[/h] 33.9% of individuals showed pre-vaccine protective antibodies (≥1/40) against B/Yamagata lineage and 41.4% against B/Victoria lineage. The annual trivalent vaccine induced significant homologous seroconversion in 14-35.6% of individuals in each vaccine campaign.
[h=4]CONCLUSIONS:[/h] The population ≥65 years has low-moderate seroprotection against B influenza lineages. Trivalent vaccination induced a slight increase of seroprotection. The trivalent vaccine should be administered to all individuals ≥65 years in all vaccine campaigns.
Copyright ? 2017 Elsevier Espa?a, S.L.U. and Sociedad Espa?ola de Enfermedades Infecciosas y Microbiolog?a Cl?nica. All rights reserved.


[h=4]KEYWORDS:[/h] Antibodies; Anticuerpos; Influenza B lineages; Linajes de gripe B; Trivalent influenza vaccination; Vacuna trivalente de gripe

PMID: 29179984 DOI: 10.1016/j.eimc.2017.10.021
 
Back
Top Bottom